[1] CAO M, LI H, SUN D, et al. Current cancer burden in China: epidemiology, etiology, and prevention[J]. Cancer Biology & Medicine, 2022, 19(8): 11211138.
[2] WANG R, LIAN J, WANG X, et al. Survival rate of colorectal cancer in China: A systematic review and meta-analysis[J]. Frontiers in Oncology, 2023, 13: 1033154.
[3] CP W, E W, BW S. World Cancer Report: Cancer Research for Cancer Prevention[M].
[2024].
[4] SAWICKI T, RUSZKOWSKA M, DANIELEWICZ A, et al. A Review of Colorectal Cancer in Terms of Epidemiology, Risk Factors, Development, Symptoms and Diagnosis[J]. Cancers, 2021, 13(9): 2025.
[5] SIEGEL R L, WAGLE N S, CERCEK A, et al. Colorectal cancer statistics, 2023[J]. CA: A Cancer Journal for Clinicians, 2023, 73(3): 233-254.
[6] PATEL S G, KARLITZ J J, YEN T, et al. The rising tide of early-onset colorectal cancer: a comprehensive review of epidemiology, clinical features, biology, risk factors, prevention, and early detection[J]. The Lancet Gastroenterology & Hepatology, 2022, 7(3): 262-274.
[7] MALKI A, ELRUZ R A, GUPTA I, et al. Molecular Mechanisms of Colon Cancer Progression and Metastasis: Recent Insights and Advancements[J]. International Journal of Molecular Sciences, 2021, 22(1): 130.
[8] LOTFOLLAHZADEH S, KASHYAP S, TSORIS A, et al. Rectal Cancer[M]//StatPearls. Treasure Island (FL): StatPearls Publishing, 2023.
[9] LOTFOLLAHZADEH S, RECIO-BOILES A, CAGIR B. Colon Cancer[M]//StatPearls. Treasure Island (FL): StatPearls Publishing, 2023.
[10] NGUYEN L H, GOEL A, CHUNG D C. Pathways of Colorectal Carcinogenesis[J]. Gastroenterology, 2020, 158(2): 291-302.
[11] LI S Y, YANG M Q, LIU Y M, et al. Endoscopic and pathological characteristics of de novo colorectal cancer: Retrospective cohort study[J]. World Journal of Gastroenterology, 2023, 29(18): 2836-2849.
[12] KEUM N, GIOVANNUCCI E. Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies[J]. Nature Reviews Gastroenterology & Hepatology, 2019, 16(12): 713-732.
[13] KASI A, HANDA S, BHATTI S, et al. Molecular Pathogenesis and Classification of Colorectal Carcinoma[J]. Current colorectal cancer reports, 2020, 16(5): 97-106.
[14] EAST J E, ATKIN W S, BATEMAN A C, et al. British Society of Gastroenterology position statement on serrated polyps in the colon and rectum[J]. Gut, 2017, 66(7): 1181-1196.
[15] AIDERUS A, BARKER N, TERGAONKAR V. Serrated colorectal cancer: preclinical models and molecular pathways[J]. Trends in cancer, 2024, 10(1): 76-91.
[16] MUELLER J D, BETHKE B, STOLTE M. Colorectal de novo carcinoma: a review of its diagnosis, histopathology, molecular biology, and clinical relevance[J]. Virchows Archiv, 2002, 440(5): 453-460.
[17] KUDO S, KASHIDA H, TAMURA T. Early colorectal cancer: Flat or depressed type[J]. Journal of Gastroenterology and Hepatology, 2000, 15(s1): 66-70.
[18] HOSSAIN M S, KARUNIAWATI H, JAIROUN A A, et al. Colorectal Cancer: A Review of Carcinogenesis, Global Epidemiology, Current Challenges, Risk Factors, Preventive and Treatment Strategies[J]. Cancers, 2022, 14(7): 1732.
[19] ALZAHRANI S M, AL DOGHAITHER H A, AL-GHAFARI A B. General insight into cancer: An overview of colorectal cancer (Review)[J]. Molecular and Clinical Oncology, 2021, 15(6): 271.
[20] TARIQ K, GHIAS K. Colorectal cancer carcinogenesis: a review of mechanisms[J]. Cancer Biology & Medicine, 2016, 13(1): 120-135.
[21] MÁRMOL I, SÁNCHEZ-DE-DIEGO C, PRADILLA DIESTE A, et al. Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer[J]. International Journal of Molecular Sciences, 2017, 18(1): 197.
[22] NOJADEH J N, BEHROUZ SHARIF S, SAKHINIA E. Microsatellite instability in colorectal cancer[J]. EXCLI Journal, 2018, 17: 159-168.
[23] SULLIVAN B A, NOUJAIM M, ROPER J. Cause, Epidemiology, and Histology of Polyps and Pathways to Colorectal Cancer[J]. Gastrointestinal endoscopy clinics of North America, 2022, 32(2): 177-194.
[24] AMATO M, FRANCO R, FACCHINI G, et al. Microsatellite Instability: From the Implementation of the Detection to a Prognostic and Predictive Role in Cancers[J]. International Journal of Molecular Sciences, 2022, 23(15): 8726.
[25] LEE J E, KIM M Y. Cancer epigenetics: Past, present and future[J]. Seminars in Cancer Biology, 2022, 83: 4-14.
[26] RASKOV H, SØBY J H, TROELSEN J, et al. Driver Gene Mutations and Epigenetics in Colorectal Cancer[J]. Annals of Surgery, 2020, 271(1): 75.
[27] GUTIERREZ A, DEMOND H, BREBI P, et al. Novel Methylation Biomarkers for Colorectal Cancer Prognosis[J]. Biomolecules, 2021, 11(11): 1722.
[28] ZHANG X, DONG Z, CUI H. Interplay between Epigenetics and CellularMetabolism in Colorectal Cancer[J]. Biomolecules, 2021, 11(10): 1406.
[29] POIRIER J T, GARDNER E E, CONNIS N, et al. DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2[J]. Oncogene, 2015, 34(48): 5869-5878.
[30] SABATUCCI A, BERCHET V, BELLIA F, et al. A new methodological approach for in vitro determination of the role of DNA methylation on transcription factor binding using AlphaScreen® analysis: Focus on CREB1 binding at hBDNF promoter IV[J]. Journal of Neuroscience Methods, 2020, 341: 108720.
[31]ZHANG J, YANG C, WU C, et al. DNA Methyltransferases in Cancer: Biology, Paradox, Aberrations, and Targeted Therapy[J]. Cancers, 2020, 12(8): 2123.
[32] SU R, WU X, TAO L, et al. The role of epigenetic modifications in Colorectal Cancer Metastasis[J]. Clinical & Experimental Metastasis, 2022, 39(4): 521539.
[33] NEJA S A. Site-Specific DNA Demethylation as a Potential Target for Cancer Epigenetic Therapy[J]. Epigenetics Insights, 2020, 13: 2516865720964808.
[34] ORYANI M A, TAVASOLI A, GHALAVAND M A, et al. Epigenetics and its therapeutic potential in colorectal cancer[J]. Epigenomics, 2022, 14(11): 683697.
[35] ONODERA A, GONZÁLEZ-AVALOS E, LIO C W J, et al. Roles of TET and TDG in DNA demethylation in proliferating and non-proliferating immune cells[J]. Genome Biology, 2021, 22(1): 186.
[36] DAI X, REN T, ZHANG Y, et al. Methylation multiplicity and its clinical values in cancer[J]. Expert Reviews in Molecular Medicine, 2021, 23: e2.
[37] YANO N, FEDULOV A V. Targeted DNA Demethylation: Vectors, Effectors and Perspectives[J]. Biomedicines, 2023, 11(5): 1334.
[38] FAROOQI A A, FAYYAZ S, POLTRONIERI P, et al. Epigenetic deregulation in cancer: Enzyme players and non-coding RNAs[J]. Seminars in Cancer Biology, 2022, 83: 197-207.
[39] GRADY W M. Chapter Eleven - Epigenetic alterations in the gastrointestinal tract: Current and emerging use for biomarkers of cancer[M]//BERGER F G, BOLAND C R. Advances in Cancer Research: Vol. 151. Academic Press, 2021: 425-468.
[40] FATEMI N, TIERLING S, ES H A, et al. DNA methylation biomarkers in colorectal cancer: Clinical applications for precision medicine[J]. International Journal of Cancer, 2022, 151(12): 2068-2081.
[41] JUNG G, HERNÁNDEZ-ILLÁN E, MOREIRA L, et al. Epigenetics of colorectal cancer: biomarker and therapeutic potential[J]. Nature Reviews Gastroenterology & Hepatology, 2020, 17(2): 111-130.
[42] ASHKTORAB H, BRIM H. DNA Methylation and Colorectal Cancer[J]. Current Colorectal Cancer Reports, 2014, 10(4): 425-430.
[43] YI J M. DNA Methylation Change Profiling of Colorectal Disease: Screening towards Clinical Use[J]. Life (Basel, Switzerland), 2021, 11(5): 412.
[44] CERVENA K, SISKOVA A, BUCHLER T, et al. Methylation-Based Therapies for Colorectal Cancer[J]. Cells, 2020, 9(6): 1540.
[45] NEPALI K, LIOU J P. Recent developments in epigenetic cancer therapeutics: clinical advancement and emerging trends[J]. Journal of Biomedical Science, 2021, 28(1): 27.
[46] FENG S, DE CARVALHO D D. Clinical advances in targeting epigenetics for cancer therapy[J]. The FEBS Journal, 2022, 289(5): 1214-1239.
[47] LU Y, CHAN Y T, TAN H Y, et al. Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy[J]. Molecular Cancer, 2020, 19(1): 79.
[48] BABAR Q, SAEED A, TABISH T A, et al. Novel epigenetic therapeutic strategies and targets in cancer[J]. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2022, 1868(12): 166552.
[49] GNYSZKA A, JASTRZEBSKI Z, FLIS S. DNA methyltransferase inhibitors and their emerging role in epigenetic therapy of cancer[J]. Anticancer Research, 2013, 33(8): 2989-2996.
[50] DAHER-REYES G S, MERCHAN B M, YEE K W L. Guadecitabine (SGI-110): an investigational drug for the treatment of myelodysplastic syndrome and acute myeloid leukemia[J]. Expert Opinion on Investigational Drugs, 2019, 28(10): 835-849.
[51] GROS C, FLEURY L, NAHOUM V, et al. New Insights on the Mechanism of Quinoline-based DNA Methyltransferase Inhibitors[J]. The Journal of Biological Chemistry, 2015, 290(10): 6293-6302.
[52] AMATO R J. Inhibition of DNA Methylation by Antisense Oligonucleotide MG98 as Cancer Therapy[J]. Clinical Genitourinary Cancer, 2007, 5(7): 422426.
[53] CAULFIELD T, MEDINA-FRANCO J L. Molecular dynamics simulations of human DNA methyltransferase 3B with selective inhibitor nanaomycin A[J]. Journal of Structural Biology, 2011, 176(2): 185-191.
[54] SHERMAN D J, LI J. Proteasome Inhibitors: Harnessing Proteostasis to Combat Disease[J]. Molecules, 2020, 25(3): 671.
[55] ZHAO L, ZHAO J, ZHONG K, et al. Targeted protein degradation: mechanisms, strategies and application[J]. Signal Transduction and Targeted Therapy, 2022, 7(1): 1-13.
[56] HANLEY S E, COOPER K F. Sorting Nexins in Protein Homeostasis[J]. Cells, 2020, 10(1): 17.
[57] LI Y, LI S, WU H. Ubiquitination-Proteasome System (UPS) and Autophagy Two Main Protein Degradation Machineries in Response to Cell Stress[J]. Cells, 2022, 11(5): 851.
[58] HÖHFELD J, CYR D M, PATTERSON C. From the cradle to the grave: molecular chaperones that may choose between folding and degradation[J]. EMBO Reports, 2001, 2(10): 885-890.
[59] ZHANG X, LINDER S, BAZZARO M. Drug Development Targeting the Ubiquitin–Proteasome System (UPS) for the Treatment of Human Cancers[J]. Cancers, 2020, 12(4): 902.
[60] MORGAN J J, CRAWFORD L J. The Ubiquitin Proteasome System in Genome Stability and Cancer[J]. Cancers, 2021, 13(9): 2235.
[61] ZHANG L, WU M, SU R, et al. The Efficacy and Mechanism of Proteasome Inhibitors in Solid Tumor Treatment[J]. Recent Patents on Anti-Cancer Drug Discovery, 2022, 17(3): 268-283.
[62] NARAYANAN S, CAI C Y, ASSARAF Y G, et al. Targeting the ubiquitinproteasome pathway to overcome anti-cancer drug resistance[J]. Drug Resistance Updates, 2020, 48: 100663.
[63] LAPLANTE G, ZHANG W. Targeting the Ubiquitin-Proteasome System for Cancer Therapeutics by Small-Molecule Inhibitors[J]. Cancers, 2021, 13(12): 3079.
[64] FRICKER L D. Proteasome Inhibitor Drugs[J]. Annual Review of Pharmacology and Toxicology, 2020, 60(1): 457-476.
[65] PARK J, CHO J, SONG E J. Ubiquitin–proteasome system (UPS) as a target for anticancer treatment[J]. Archives of Pharmacal Research, 2020, 43(11): 1144-1161.
[66] RAMADAN K, MEERANG M. Degradation-linked ubiquitin signal and proteasome are integral components of DNA double strand break repair: New perspectives for anti-cancer therapy[J]. FEBS letters, 2011, 585(18): 28682875.
[67] DATTA K, SUMAN S, KUMAR S, et al. Colorectal Carcinogenesis, Radiation Quality, and the Ubiquitin-Proteasome Pathway[J]. Journal of Cancer, 2016, 7(2): 174.
[68] GAZZAROLI G, ANGELI A, GIACOMINI A, et al. Proteasome inhibitors as anticancer agents[J]. Expert Opinion on Therapeutic Patents, 2023, 33(11): 775-796.
[69] KIM Y M, KIM H J. Proteasome Inhibitor MG132 is Toxic and Inhibits the Proliferation of Rat Neural Stem Cells but Increases BDNF Expression to Protect Neurons[J]. Biomolecules, 2020, 10(11): 1507.
[70] SCHMIDT B, UMBREEN S, BRAUN H, et al. Mimetic Peptides and the Use Thereof in the Form of 20S, 26S and Immunoproteasome Inhitibors: 20090012007[P]. 2009-01-08.
[71] MLYNARCZUK-BIALY I, DOEPPNER T R, GOLAB J, et al. Biodistribution and Efficacy Studies of the Proteasome Inhibitor BSc2118 in a Mouse Melanoma Model[J]. Translational Oncology, 2014, 7(5): 570-579.
[72] KISSELEV A F, GOLDBERG A L. Proteasome inhibitors: from research tools to drug candidates[J]. Chemistry & Biology, 2001, 8(8): 739-758.
[73] KANE R C, BROSS P F, FARRELL A T, et al. Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy[J]. The Oncologist, 2003, 8(6): 508-513.
[74] APPAVU R, MOHAN D. Bortezomib in Anti-Cancer Activity: A Potential Drug. Global Journal of Cancer Therapy[J]. Global Journal of Cancer Therapy, 2016, 2: 005-008.
[75] ALWAHSH M, FARHAT J, TALHOUNI S, et al. Bortezomib advanced mechanisms of action in multiple myeloma, solid and liquid tumors along with its novel therapeutic applications[J]. EXCLI Journal, 2023, 22: 146-168.
[76] CALDIRAN F, BERKEL C, YILMAZ E, et al. Combination treatment of bortezomib and epirubicin increases the expression of TNFRSF10 A/B, and induces TRAIL-mediated cell death in colorectal cancer cells[J]. Biochemical and Biophysical Research Communications, 2023, 675: 33-40.
[77] CHATTOPADHYAY N, BERGER A J, KOENIG E, et al. KRAS Genotype Correlates with Proteasome Inhibitor Ixazomib Activity in Preclinical In Vivo Models of Colon and Non-Small Cell Lung Cancer: Potential Role of Tumor Metabolism[J]. PLOS ONE, 2015, 10(12): e0144825.
[78] YUE D, SUN X. Ixazomib promotes CHOP-dependent DR5 induction and apoptosis in colorectal cancer cells[J]. Cancer Biology & Therapy, 2019, 20(3): 284-294.
[79] SUGUMAR D, KELLER J, VIJ R. Targeted treatments for multiple myeloma: specific role of carfilzomib[J]. Pharmacogenomics and Personalized Medicine, 2015, 8: 23-33.
[80] TANG W, SU G, LI J, et al. Enhanced anti-colorectal cancer effects of carfilzomib combined with CPT-11 via downregulation of nuclear factor-κB in vitro and in vivo[J]. International journal of oncology, 2014, 45.
[81] ASHER G, SHAUL Y. p53 proteasomal degradation: poly-ubiquitination is not the whole story[J]. Cell cycle (Georgetown, Tex.), 2005, 4(8): 1015-1018.
[82] XU Z, WU W, YAN H, et al. Regulation of p53 stability as a therapeutic strategy for cancer[J]. Biochemical Pharmacology, 2021, 185: 114407.
[83] KOCATURK N M, GOZUACIK D. Crosstalk Between Mammalian Autophagy and the Ubiquitin-Proteasome System[J]. Frontiers in Cell and Developmental Biology, 2018, 6.
[84] PENG Y, WANG Y, ZHOU C, et al. PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?[J]. Frontiers in Oncology, 2022, 12: 819128.
[85] POPOVA N V, JÜCKER M. The Role of mTOR Signaling as a Therapeutic Target in Cancer[J]. International Journal of Molecular Sciences, 2021, 22(4): 1743.
[86] LEE B J, BOYER J A, BURNETT G L, et al. Selective Inhibitors of mTORC1 Activate 4EBP1 and Suppress Tumor Growth[J]. Nature chemical biology, 2021, 17(10): 1065-1074.
[87] TEWARI D, PATNI P, BISHAYEE A, et al. Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: A novel therapeutic strategy[J]. Seminars in Cancer Biology, 2022, 80: 1-17.
[88] GLAVIANO A, FOO A S C, LAM H Y, et al. PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer[J]. Molecular Cancer, 2023, 22(1): 138.
[89] LI Q, LAI Z, YAN Z, et al. Hedyotis diffusa Willd inhibits proliferation and induces apoptosis of 5‑FU resistant colorectal cancer cells by regulating the PI3K/AKT signaling pathway[J]. Molecular Medicine Reports, 2018, 17(1): 358-365.
[90] WU W K K, VOLTA V, CHO C H, et al. Repression of protein translation and mTOR signaling by proteasome inhibitor in colon cancer cells[J]. Biochemical and Biophysical Research Communications, 2009, 386(4): 598-601.
[91] AFIFY S M, OO A K K, HASSAN G, et al. How can we turn the PI3K/AKT/mTOR pathway down? Insights into inhibition and treatment of cancer[J]. Expert Review of Anticancer Therapy, 2021, 21(6): 605-619.
[92] POLITZ O, SIEGEL F, BÄRFACKER L, et al. BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signalingdependent tumor growth in mouse models[J]. International Journal of Cancer, 2017, 140(2): 449-459.
[93] HUANG X, YOU L, NEPOVIMOVA E, et al. Inhibitors of phosphoinositide 3-kinase (PI3K) and phosphoinositide 3-kinase-related protein kinase family (PIKK)[J]. Journal of Enzyme Inhibition and Medicinal Chemistry, 2023, 38(1): 2237209.
[94] GOU P, ZHANG W. Protein lysine acetyltransferase CBP/p300: A promising target for small molecules in cancer treatment[J]. Biomedicine & Pharmacotherapy, 2024, 171: 116130.
[95] CHEN Q, YANG B, LIU X, et al. Histone acetyltransferases CBP/p300 in tumorigenesis and CBP/p300 inhibitors as promising novel anticancer agents[J]. Theranostics, 2022, 12(11): 4935-4948.
[96] SUNDARESAN N R, PILLAI V B, WOLFGEHER D, et al. The Deacetylase SIRT1 Promotes Membrane Localization and Activation of Akt and PDK1 During Tumorigenesis and Cardiac Hypertrophy[J]. Science Signaling, 2011, 4(182): ra46-ra46.
[97] CHEN J, LI Q. Life and death of transcriptional co-activator p300[J]. Epigenetics, 2011, 6(8): 957-961.
[98] ADEGOKE O A J, BEATTY B E, KIMBALL S R, et al. Interactions of the super complexes: When mTORC1 meets the proteasome[J]. The International Journal of Biochemistry & Cell Biology, 2019, 117: 105638.
[99] GIRI A K, AITTOKALLIO T. DNMT Inhibitors Increase Methylation in the Cancer Genome[J]. Frontiers in Pharmacology, 2019, 10: 385.
[100] HAERTLE L, BUENACHE N, CUESTA HERNÁNDEZ H N, et al. Genetic Alterations in Members of the Proteasome 26S Subunit, AAA-ATPase (PSMC) Gene Family in the Light of Proteasome Inhibitor Resistance in Multiple Myeloma[J]. Cancers, 2023, 15(2): 532.
[101] SHI C X, KORTÜM K M, ZHU Y X, et al. CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple Myeloma[J]. Molecular Cancer Therapeutics, 2017, 16(12): 2862-2870.
[102] TSVETKOV P, MENDILLO M L, ZHAO J, et al. Compromising the 19S proteasome complex protects cells from reduced flux through the proteasome[J]. eLife, 4: e08467.
修改评论